Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan's Price Reform Pledge: Will Others Follow?

Executive Summary

Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.

Advertisement

Related Content

Allergan Confident About Continued Growth, Swats Down Competition Concerns
The New World Of Pharma – Markets, Messaging And The Flash Mob
Pharma Strategizes On Drug Pricing On Day One Of J.P. Morgan
What Does 2017 Hold For Pharma?
Expect Industry To Step Up Drug Pricing Self-Regulation In 2017 – PwC
Trump’s Drug Pricing Remarks: A Gambit For Industry Self-Restraint?
Trump Win Is False Security For Drug Makers, Allergan CEO Warns
Clinton's Plan To Tame 'Unjustified' Drug Prices: Who's At Risk?
More Than 'That Old Shkreli Co.,' KaloBios Ready To Innovate, Change Biotech
EpiPen's Swollen Price May Trigger Patient Assistance Program Probes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097255

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel